Immunosuppressants I

Question 1

cyclosporine MOA

Answer 1

inhibitor of calcineurin
binds cyclophilin

block T cell activation - prevent IL-2 transcription

Question 2

adverse cyclosporine

Answer 2

nephrotoxic

gingival hyperplasia
hirsutism

Question 3

tacrolimus MOA

Answer 3

aka - FK506

inhibitor of calcineurin
bind FKBP

block T cell activation - prevent IL-2 transcription

Question 4

tacrolimus adverse

Answer 4

nephrotixic

diabetes and neurotoxicity

Question 5

sirolimus

Answer 5

aka rapamycin

inhibitor of mTOR
bind FKBP

block T cell activation and B cell activation

prevent response to IL-2

Question 6

adverse sirolimus

Answer 6

not nephrotoxic

anemia, thrombocytopenia, leukopenia, insulin resistance, hyperlipidemia

Question 7

daclizumab

Answer 7

mAb - block IL-2R

Question 8

basiliximab

Answer 8

mAb - block IL-2R

Question 9

axathioprine

Answer 9

precursor - 6-MP

inhibit lymphocyte proliferation - inhibit nucleotide synthesis

Question 10

azathioprine adverse

Answer 10

degraded xanthine oxidase

more toxic with allopurinol

Question 11

glucocorticoids

Answer 11

inhibit NF-KB

suppress T and B cell function
-decreased transcription of cytokines

Question 12

adverse glucocorticoids

Answer 12

cushing syndrome

Question 13

tx of transplant rejection

Answer 13

cyclosporine
tacrolimus
sirolimus
daclizumab
basiliximab
azathioprine
glucocorticoids

Question 14

aldesleukin

Answer 14

recombinant IL-2

tx - renal cell carcinoma
metastatic melanoma

Question 15

epoetin alfa

Answer 15

recombinant EPO

tx anemias

Question 16

filgrastim

Answer 16

recombinant G-CSF

recovery of bone marrow

Question 17

sargramostim

Answer 17

recombinant - GM-CSF

recovery of bone marrow

Question 18

IFN-a recombinant

Answer 18

tx chronic hep B and C
kaposi sarcoma
malignant melanoma

Question 19

IFN-B recombinant

Answer 19

tx MS

Question 20

IFN-gamma recombinant

Answer 20

tx chronic granulomatous disease

Question 21

romoplostim

Answer 21

recombinant cytokine

for thrombocytopenia

Question 22

oprelvekin

Answer 22

recombinant IL-11

tx thromboctopenia

Question 23

alemtuzumab

Answer 23

CD52

tx CLL

Question 24

bebacizumab

Answer 24

VEGF

Question 25

cetuximab

Answer 25

EFGR

stage IV colorectal cancer

Question 26

rituximab

Answer 26

CD20

B-cell non hodgkin lmyphoma
CLL
RA
ITP

Question 27

trastuzumab

Answer 27

HER2/neu

breast cancer

Question 28

adalimumab

Answer 28

soluble TNF-a

Question 29

etanercept

Answer 29

decoy TNF-a receptor

Question 30

infliximab

Answer 30

soluble TNF-a

Question 31

eculizumab

Answer 31

complement C5

tx - paroxysmal nocturnal hemoglobinuria

Question 32

natalizumab

Answer 32

a4 - integrin

MS
crohn disease

Question 33

risk of PML pt with JC virus

Answer 33

natalizumab - a4 integrin - WBC adhesion

Question 34

abciximab

Answer 34

platelet IIb/IIIa

2 x 3 = six = ab six imab

antiplatelet - prevent ischemic complications during percutaneous coronary intervention

Question 35

denosumab

Answer 35

RANK-L

osteoporosis tx
-inhibit osteoclast activity

denOSumab

Question 36

digoxin immune Fab

Answer 36

digoxin - antidote toxicity

Question 37

omalizumab

Answer 37

IgE

allergic asthma
-revent IgE binding Fc E RI

Question 38

palivizumab

Answer 38

RSV F protein

RSV prophylaxis - high risk infant

Question 39

ranibizumab

Answer 39

VEGF

tx neovascular macular degeneration

Question 40

bebacizumab

Answer 40

VEGF